The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression

The PI3K-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression by Lisa Rohrbacher https://t.co/WAmvSPor6a

New article: The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression https://t.co/xvL1pnalAY #CLL #leusm #hematology

Researchers from @LMU_Muenchen showed that idelalisib might contribute to an increased risk of infections regardless of the underlying B-cell malignancy. #leukemia 📌 @FrontImmunol 🔗 https://t.co/37PByYBdKt https://t.co/0rJ0tynOhv